Cannabis is big business, so it was only a matter of time before someone filed a consumer class action claiming that his cannabis was schwag. It happened in Illinois, where a judge in the Northern District promptly shot it down—not because the plaintiff’s theory was necessarily wrong, but because his theory of deception was a
Sometimes we feel as though we have gone back in time. The Super Bowl is in San Francisco this week, as it was 10 years ago, although this time around, the atrium lobby of our building has been converted into an ESPN studio. We are the temporary home of the Rich Eisen Show, with the
The Avandia MDL has been a long, winding, and ultimately meritless road. The FDA approved the drug to treat Type II diabetes in 1999, and the MDL got going in 2007, after a widely publicized, but ultimately disproven meta-analysis purported to show that Avandia presented an increased risk of heart attacks.
That was 18 years
We reported a few months ago on a California court that largely gutted a pharma-related privacy class action centered on the alleged disclosure of personal information through the use of computer pixels. Today we bring you another pixel case, but with a different outcome. In Jancik v. WebMD LLC, No. 1:22-cv-644, 2025 U.S. Dist.
In Knapp v. Zoetis Inc., 2021 U.S. Dist. Lexis 63783 (E.D. Va. March 31, 2021), the plaintiff alleged that administration of an equine antibiotic caused his horse, Boomer, to experience “persistent lameness” and permanent damage to the “musculature in his neck.” Boomer was not okay. His condition was far from stable.
The plaintiff claimed
We have blogged about class actions; we have blogged about preemption; we have blogged about social media; we have blogged about alleged economic loss; and we have blogged about alleged product defects—endlessly. Rarely, however, have we blogged on all of these topics in a single post.
Today is the day, and the topic is an
The Third Circuit issued a gem of an opinion on class certification last month, and we like it because it puts a laser focus on what a plaintiff has to prove to get a class certified and the district court’s duty to examine and resolve disputes at the class certification stage. In In re Lamictal